Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 14/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 14/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 14/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 14/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 14/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 14/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15062288 | 0.84 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16402393 | 0.84 | NR4A1 (0.50) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL511511 | 0.84 | NR4A1 (0.54) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1037346 | 0.82 | NR4A1 (0.49) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21195190 | 0.82 | NR4A1 (0.49) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL16402312 | 0.82 | NR4A1 (0.53) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL2480936 | 0.82 | NR4A1 (0.53) | NR4A1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL20047851 | 0.82 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL361336 | 0.81 | TSHR (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL20085560 | 0.80 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476670-B | Bicyclic heteroaryl derivatives | 豪夫迈·罗氏有限公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-109311878-B | Triazolopyridines as gamma-secretase modulators | 豪夫迈·罗氏有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-109415369-B | Fused pyrimidine derivatives | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475279-B1 | TRIAZOLOPYRIDINES AS GAMMA-SECRETASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2021-07-14 | — | — | EP | disclosed |
| EP-3475279-B1 | TRIAZOLOPYRIDINES AS GAMMA-SECRETASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2021-07-14 | — | — | EP | disclosed |
| EP-3481829-B1 | FUSED PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-04-07 | — | — | EP | disclosed |
| EP-3523304-B1 | BICYCLIC HETEROARYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10875854-B2 | Triazolopyridines | HOFFMANN-LA ROCHE INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875854-B2 | Triazolopyridines | HOFFMANN-LA ROCHE INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-22 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| EP-2379553-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | Bristol-Myers Squibb Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-20 | — | — | US | disclosed |
| WO-2010083141-A1 | BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | NR4A1 3431/4885PSEN1 7/4885PSEN2 6/4885 |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | NR4A1 3431/4885PSEN1 7/4885PSEN2 6/4885 |
| US-20110015175-A1 | Bicyclic Compounds for the Reduction of Beta-Amyloid Production | APP, BACE1, APBA1 | NR4A1 3165/4885PSEN1 6/4885PSEN2 7/4885 |
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | NR4A1 2639/4885PSEN1 4398/4885PSEN2 4353/4885 |
| US-10875854-B2 | Triazolopyridines | HTR2A, APP, PTGDR | NR4A1 2151/4885PSEN1 14/4885PSEN2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.